Entera Bio Ltd. (ENTX)
Full history for every metric is available with a Kvantra account
No price history available.
Key financial summary
Financials in USDTTM unavailable| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Total revenue | $m | 0 | 1 | 0 | 0 | 0 | 0 | - | - |
| Operating profit | $m | -12 | - | ||||||
| Net profit | $m | -11 | -12 | -13 | -9 | -10 | -11 | - | -19 |
| EPS reported | $ | -0.25 | - | ||||||
| Operating cashflow per share | $ | -0.16 | - | ||||||
| Capex per share | $ | 0.00 | - | ||||||
| FCF per share | $ | -0.16 | - | ||||||
| Free cash flow | $m | -7 | - | ||||||
| Net debt | $m | -7 | - | ||||||
| Book value equity | $m | 13 | - | ||||||
| Book value per share | $ | 0.28 | - | ||||||
| Number of shares | m | 46.19 | - | ||||||
| DPS (TTM paid) | $ | 0.00 | - |
Financial summary
Financials in USDTTM unavailable| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Value | |||||||||
| P/E TTM | x | - | - | ||||||
| P/B LTM | x | 6.84 | - | ||||||
| P/S LTM | x | 2,133.59 | - | ||||||
| P/FCF LTM | x | -11.98 | - | ||||||
| EV/EBITDA LTM | x | -7.27 | - | ||||||
| EV/Sales LTM | x | 1,976.02 | - | ||||||
| Earnings Yield LTM | % | -12.77% | - | ||||||
| FCF Yield | % | -8.34% | - | ||||||
| Quality | |||||||||
| ROE | % | -87.31% | - | ||||||
| ROIC | % | -2.19% | - | ||||||
| Operating margin | % | -274.50% | - | ||||||
| Gross margin | % | 0.00% | - | ||||||
| FCF/Sales | % | -17802.4% | - | ||||||
| Growth and momentum | |||||||||
| EPS Growth YoY | % | - | - | ||||||
| Sales Growth YoY | % | -76.80% | - | ||||||
| Net Income Growth YoY | % | - | - | ||||||
| FCF Growth | % | - | - | ||||||
| Operating Profit Growth | % | - | - | ||||||
| Dividend and capital structure | |||||||||
| Dividend Yield | % | 0.00% | - | ||||||
| Dividend Growth | % | - | - | ||||||
| Payout Ratio | % | 0.00% | - | ||||||
| FCF/Debt | x | -15.26 | - | ||||||
| Net Debt/EBITDA | x | 0.58 | - | ||||||
| EBIT/Net interest | x | 0.00 | - | ||||||
| Net debt/market cap | % | +0.29% | - | ||||||
| Net debt/Equity | x | -0.52 | - | ||||||
| Gross debt/equity | x | 0.04 | - | ||||||
Price target estimates
Based on consensus from external analysts. Not Kvantra's opinion.
Ratings
Based on consensus from external analysts. Not Kvantra's opinion.
ESG
| Metric | 2024 | 2025 | 2026 |
|---|---|---|---|
| ESG-score | |||
| Environmental score | |||
| Social score | |||
| Governance score | |||
| Risk rating |
Company overview
Entera Bio Ltd. is a biopharmaceutical firm in the clinical development phase, dedicated to creating and marketing oral medications composed of large molecules, addressing medical conditions that currently lack adequate treatments. Its primary experimental drugs are EB612, currently undergoing Phase II clinical assessment for hypoparathyroidism, and EB613, which has concluded Phase II studies for osteoporosis and is now in Phase I trials for treating non-healing bone fractures. Furthermore, the company holds a collaborative research and licensing pact with Amgen Inc. aimed at identifying and advancing potential therapeutic compounds for inflammatory conditions and other grave ailments. Established in 2009, Entera Bio Ltd. operates from its headquarters in Jerusalem, Israel.
Similar companies
For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.
No price history available.
Consensus from external analysts. Not Kvantra's opinion.
Based on consensus from external analysts. Not Kvantra's opinion.
Entera Bio Ltd. is a biopharmaceutical firm in the clinical development phase, dedicated to creating and marketing oral medications composed of large molecules, addressing medical conditions that currently lack adequate treatments. Its primary experimental drugs are EB612, currently undergoing Phase II clinical assessment for hypoparathyroidism, and EB613, which has concluded Phase II studies for osteoporosis and is now in Phase I trials for treating non-healing bone fractures. Furthermore, the company holds a collaborative research and licensing pact with Amgen Inc. aimed at identifying and advancing potential therapeutic compounds for inflammatory conditions and other grave ailments. Established in 2009, Entera Bio Ltd. operates from its headquarters in Jerusalem, Israel.
Unlock all fundamental data
Sign up for FreeUnlock all fundamental data
Sign up for Free